This DataWatch presents estimates of the health care charges for adults who are diagnosed and treated for depression in primary care. More than nine out of ten of these adults sought care for at least one nondepressive illness during the year following treatment initiation. On average, these conditions accounted for more than 70 percent of the total charges. Attempts to manage the costs of caring for depressed persons must consider the impact of nondepressive illness.
D
epressive illness is among the most common disorders seen in primary care and is associated with high rates of chronic disability and other functional impairment. Depressed patients frequently suffer from other mental and general medical disorders or may have somatic symptoms that are easily attributed to physical illness. 1 Alternatively, medical conditions may produce symptoms resembling depression or may precipitate a depressive episode. 2 These considerations make depression very difficult to recognize in the general medical setting; in fact, only half of all patients with depression are correctly diagnosed. 3 Depressed patients also are said to be high users of medical resources, in both mental health specialty and general medical settings. 4 Those with depressive illness consume two to four times more general medical resources than do patients without mental illness. In spite of years of study, however, it is unclear whether appropriate treatment of depressive or other mental illness is associated with more than very modest offsets in treatment costs associated with somatic illness. 5 However, care for depressive illness has evolved over the past decade. New innovations such as selective serotonin reuptake inhibitors (SSRIs) and managed care appear to be associated with increases in use of antidepressants and reduc-© 1998 The People-to-People Health Foundation, Inc. Cambridge, Massachusetts. tions in the cost of high-quality care. 6 Could these new treatments be associated with similar reductions in the cost of treating comorbid physical illness?
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This DataWatch is the first analysis of the costs of various medical and psychiatric comorbidities in patients with depressive illness as it is commonly treated in primary care settings. We focus on a group of patients who received antidepressants as their initial treatment. Our simultaneous analysis of the cost of multiple diseases allows assessment of the relative economic burden imposed by specific categories of illness and has important implications for cost-effectiveness studies.
Data Sources And Methods
We analyzed 3,439 patients whose medical and pharmacy claims are included in the MarketScan database (MEDSTAT Group, Ann Arbor, Michigan) for [1990] [1991] [1992] [1993] [1994] . MarketScan contains comprehensive information of the medical and pharmaceutical insurance claims of approximately 700,000 persons during these years. These benefits were offered by twenty employers from around the United States and included a mix of indemnity and managed care plans. In addition to the charge data used as the outcome variables of interest, these files contain information regarding the demographic and medical characteristics of each patient, including age and sex, diagnoses, procedures, residence, location and type of service delivery, and information regarding hospital and ancillary medical care use.
Episodes of care. The main objective of this study was to estimate the expected expenditures attributable to depressive illness as opposed to those comorbid conditions that complicate depression. Our approach was to construct episodes of care for that subset of depressed patients who were initially identified and treated in primary care settings. By analyzing this subset of patients, we restricted to some degree the heterogeneity of the sample and thus the generalizability of the study. However, the majority of depressed patients initially receive treatment in a primary care setting, and this group is the major focus of recent guidelines. 7 We began constructing episodes of care by identifying an index prescription for an antidepressant that was temporally linked to a claim for a depressive illness by no more than thirty days. To identify new episodes of treatment with antidepressants, we identified a six-month pretreatment period free of any indication of diagnosis or treatment for depressive illness. Indicators of comorbid conditions could occur at any time during the one-year treatment period following the index prescription. Total health care charges, including charges for physician visits, other outpatient visits, laboratory tests, radiological tests, hospital stays, and prescriptions, were collected over the twelve-month period after the index prescription for each patient.
Multivariate models. For this analysis we estimated several sets of multiple regression expenditure models. These estimates were adjusted for age and sex, type of depressive illness, and indicators of the presence of comorbid conditions. Types of depressive illness included major depressive disorder, first episode (International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] code 296.2x); major depressive disorder (MDD), recurrent (296.3x); neurotic depression (300.4); brief depressive reaction (309.0); prolonged depressive reaction (309.1); and depressive disorder, not elsewhere classified (NEC) (311). Comorbid conditions, collected at the level of ICD-9-CM codes, were classified according to major diagnostic categories (MDCs) and entered in the expenditure models.
We had observed in prior research that although total expenditures might be similar, various classes of antidepressant treatment resulted in differential distribution of service use. For example, we had observed that fluoxetine users have higher expenditures for ambulatory care but lower inpatient expenditures than do users of other antidepressants. We thus were curious to see whether this difference had something to do with the conditions for which patients might receive care. For example, one explanation for reduced hospital charges might be a reduced need for treatment complications of cardiovascular diseases. We thus split our sample into SSRI users (fluoxetine, sertraline, and paroxetine) and users of one of several older tricyclic antidepressants (TCAs), with appropriate adjustments for differences in antidepressant selection. 8 The results are reported as the predicted expenditure for the year following initiation of antidepressant treatment.
9

Results
Characteristics of patients with depression. The average age of the patients was 40.9 years, and there were many more women than men (2,488 versus 951) (Exhibit 1). The most common depression diagnosis was depression, NEC, followed by neurotic depression. Major depressive episode was relatively infrequent, even though this diagnosis is the focus of major guidelines. 10 Patients taking SSRIs were younger than TCA users.
More than 95 percent of patients had an indicator for at least one nondepression diagnosis at some time during the twelve-month follow-up period. Nondepressive mental illness was the most frequent (94.5 percent). Disorders of the ear, nose, mouth, and throat; the musculoskeletal system; and the skin also were common. TCA users were more likely to have an indicator for a neurological disorder than were SSRI users. There was a trend toward TCA use in patients with musculoskeletal, kidney, and blood disorders and with certain infections. The most common nondepressive mental illnesses were anxiety and adjustment disorders (Exhibit 2).
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11 Nonarticular rheumatic disorders such as fibromyositis and lumbago were common musculoskeletal disorders. In addition, neck pain syndromes were common neurological conditions, which further emphasizes the degree of musculoskeletal pain experienced by patients with depression. The most common cutaneous disorders were diseases of the breast, in- cluding breast cancer, which is classified as a cutaneous disorder in the MDC system. Cost impact of comorbid conditions. Predicted expenditures for patients without comorbid medical or psychiatric conditions are much lower than they are for patients with one or more comorbid conditions (Exhibit 3). To be more specific, on average, treatment of depressive illness alone represents only about 28 percent of the total charges for the depressed patients with comorbid conditions in this population ($2,279 versus $8,037 The most frequently occurring comorbid conditions, mental illnesses other than depression ("mental illness" in Exhibit 3), account for approximately $1,600 of the total charges of those episodes in which they occur. Other characteristics associated with large incremental spending included neurological disorders ($2,194 per episode), pregnancy and postpartum conditions ($1,697 per episode), and musculoskeletal conditions ($1,505 per episode). By contrast, incremental charges for most depression diagnoses were more modest, and the presence of a diagnosis of depression, NEC (the most frequently occurring depression diagnosis), is associated with lower-than-average spending. Based on these results, costs for an uncomplicated episode of depression, NEC, would be about $1,500.
After we adjusted for covariates, age and sex did not predict expenditures. To understand whether treatment choice had an effect on expected charges related to patient characteristics, we compared fluoxetine users with users of TCA as their initial treatment. There were no significant differences between SSRI and TCA users. Finally, we split our sample into those whose depressive episodes occurred in 1990-1992 (1,242 persons) and those in the larger sample. Although the larger sample size available for 1990-1994 resulted in more stable estimates, there were no substantive differences between the two analyses. We did not have complete data on benefit plans and thus were not able to study the impact of managed care on expenditure patterns.
Discussion
So, what does treatment of depression really cost? The answer depends on one's perspective. Treating an uncomplicated episode of depressive illness in this primary care population averaged a little more than $2,000, and treating the most common form was significantly less. However, depressed patients consume a disproportionate amount of medical resources: an overall average of nearly $8,000 during the year following the index prescription for an antidepressant. Clearly, treating patients with depression is very expensive, but depression-related expenditures represent only about a quarter of the total amount spent.
The number of comorbid conditions and the substantial impact these have on costs explain a great deal of the expenditure pattern. In this DataWatch we have described the impact of various medical and mental illnesses that occur in the year following initiation of antidepressant therapy on the costs of care for depressed patients who receive antidepressant medication. The results suggest that the costs related to care for depression itself make up only a small portion of the overall cost. Mental illnesses other than depression
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COST OF DEPRESSION account for nearly as much of the total cost as the cost of the underlying depressive illness. The antidepressant-treated population described here has a very high prevalence of identified medical and psychiatric comorbidity. Most epidemiological surveys of mental illness, including the National Comorbidity Survey and the Epidemiologic Catchment Area study, have examined prevalence of comorbid conditions among persons with a mental disorder, and they have documented the frequency of treatment in this population. However, the prevalence of comorbid conditions in a treated population has not been adequately studied. Gregory Simon partially addresses the issue, finding that depressed patients in primary care tend to have more chronic diseases, but our study is the first to estimate the magnitude of the issue.
12 Further study will be required to determine the degree to which insurance claims for these disorders correspond to the actual presence of disease and the effect of alternative insurance arrangements. Our preliminary work in a state Medicaid program suggests that far fewer depressed patients seek care for comorbid anxiety compared with the privately insured population included in this report.
13
Implications for health plans. Even if our estimates for the prevalence of comorbid mental illness are imprecise, depression and other mental disorders appear to go hand in hand in patients treated with antidepressants in primary care. Although the actual rate of coexistence of depression and other disorders is quite high, our findings suggest several interpretations of relevance to health plans. First, physicians often may confuse diseases with overlapping symptoms. This confusion, if true, undoubtedly would have detrimental effects on treatment choice. Second, there is some evidence that physicians alter the stated diagnosis depending on the motivation for reporting the diagnosis. Thus, insurance claims, medical records, and physicians' diaries may differ for the same patient.
14 Our analysis suggests a strategy that health plans could use to manage depressed patients more efficiently. Frequently occurring patient characteristics that are predictive of higher costs could be used to help identify patients early in the course of their illness. Because these patients are already incurring high costs, there is little for a health plan to lose by applying intensive services earlier in the course of an illness. For example, depressed patients with comorbid anxiety might be identified for early intensive patient management.
"Our analysis suggests a strategy that health plans could use to manage depressed patients more efficiently." DATAWATCH 205 Two important points can be made regarding the very high impact of nondepressive mental illnesses. First, although early, intensive management of patients with anxiety and adjustment disorders may not result in cost savings, it may offer the opportunity for improving the outcome of that care. Second, although our exclusion of patients with psychosis and substance abuse disorders limits the generalizability of our results regarding mental illness, one might predict similar results in dually diagnosed patients with these conditions. Such intensive, early intervention might resemble collaborative treatment models in which a mental health specialist resides in a primary care clinic. Various forms of these models are now being investigated. In general, the early results suggest that improvements in care occur at some moderate increase in cost, but these results have not been stratified according to comorbid conditions. 15 Our results suggest that targeting collaborative intervention would improve the cost side of the cost-effectiveness equation, but the effect on health status remains to be seen.
It is frequently said that adequate treatment of mental illness and depression should result in reductions in costs related to physical symptoms that might be related to the underlying psychiatric disorder. Our analyses suggest that most of the expected costs to depressed patients cannot be differentially altered by currently available antidepressant medications. Thus, whereas new treatments appear to reduce the cost and improve the quality of depression care, there does not appear to be a similar reduction in costs for comorbid medical illnesses.
16
Implications for cost-effectiveness research. Many health plans now use cost-effectiveness as one of several criteria for making decisions regarding coverage of new technologies. Cost-effectiveness studies of depression care are usually based on extrapolations from clinical trials or otherwise limited patient populations.
17 These studies are unlikely to capture the full range of depressed patients, especially those who are the highest cost. Because these costs appear to be related to comorbid conditions, cost-effectiveness studies based on more limited populations are likely to overstate potential cost savings and therefore overstate cost-effectiveness. W e have attempted to disaggregate charges associated with various diagnostic and demographic characteristics of depressed patients. The patients described here have a wide variety of comorbid conditions, which add considerably to their "high-utilizer" status. Based on the results presented here, we doubt that any single program (or "magic bullet") is likely to result in significant cost containment. By providing more accurate esti- yearly charges.) Since we initially had data on n = 1242 patients (and ultimately on 3439 patients), using 30 to 40 predictor variables may seem quite reasonable in the sense that we had more than 1200 (or 3400) "degrees of freedom" left over to estimate "error" and/or lack-of-…t in these models.
The truth is that even relatively small intercorrelations between thirty or more predictor variables can lead to truly "serious" multicollinearity (ill-conditioning.)
Speci…cally, least squares estimates for regression coe¢cients then have a tendency to be unstable relative to very small numerical changes in the data. [This is typically illustrated by adding random noise after the last reported decimal place in the data and/or by deleting a few observations that are not outliers!] In particular, some least squares estimates may have numerical signs that are opposite to the sign of the (marginal) correlation exhibited when log(charge) is plotted versus only that predictor variable. The sign of one of these two statistics (either the marginal correlation or the …tted coe¢cient) will usually make common sense, while the other will then seem "wrong" or "unbelievable.." Problems with numerical signs in the multiple regression models of Croghan et al.(1998) .00086 In the above table, asterisks (*) mark "wrong" sign problems that were successfully treated using maximum likelihood "ridge regression" methodology described below.
Here, one might expect that the DEP_DX4 indicator of "brief depressive episode" would be associated with low annual health care costs, but ordinary least squares estimates do not necessarily support this expectation. Similarly, treatment of depression using Prozac ( ‡uoxetine; initial n=1242 dataset) or any of the three major SSRIs ( ‡uoxetine, sertraline or paroxetine; ultimate n=3439 dataset) might well be expected to be more cost-e¤ective than using a TCA/HCA ...rather than, say, equally or less cost-e¤ective. Finally, the e¤ect of GENDER (0=male,1=female) strikes me as being most curious. The GENDER indicator is highly correlated with "male and female reproductive system" problems (STDMDC12 and STDMDC13, respectively) and with "factors in ‡uencing health" (STDMDC23) that tend to be more highly correlated with log(charges) than is GENDER alone; here are these intercorrelations within the …nal dataset (n=3439.) In other words, women consistently tended to incur higher log(charges) than men, but the GENDER indicator received "negative" credit as it battled with STDMDC codes 12, 13 and 23 for least-squares "recognition." Maximum likelihood shrinkage methodology failed (for the n=3439 dataset) to "correct" the sign of the GENDER 4 coe¢cient but at least succeeded in preventing this male-female di¤erence from being labelled "statistically signi…cant."
Regression Model Equations
A multiple linear regression model for y = log(charge) is expressed in matrix notation as
where y is a n £1 vector of observed response values; 1 is a n £1 vector of ones; X is a given n£p matrix of non-constant regressor coordinates; I is an n£n identity matrix;
¹ is the unknown intercept scalar;¯is a p£1 vector of unknown regression coe¢cients; and the responses are stochastic and uncorrelated with constant, unknown variance,
The shrinkage/ridge regression methods we used to treat observed symptoms of multicollinearity require a three-step estimation process:
(1) place the data in a canonical form that minimizes the e¤ects of one's choice for scaling of predictor variables on principal axes and coordinates, (2) estimate standardized coe¢cients using maximum likelihood methods, and (3) compute the corresponding coe¢cients for the original choice of axis scaling.
In step (1), the data are …rst "centered" by subtracting o¤ column means, so that
. In other words, centering allows the above model to be written succinctly as E(yjX) = X¯and V ar(yjX) = ¾ 2 (I ¡ 11 0 =n), where the intercept term from equation (1) is implicitly
Thus, in shrinkage/ridge regression, one's estimate for the ¹ scalar changes because the estimate of the¯vector is shrunken.
This convention assures that every shrinkage/ridge …tted hyperplane always passes through y = y at x = x, as does the …tted ordinary least squares hyperplane.
Next, step (1) also requires that each variable be rescaled by dividing its coordinates by the observed standard deviation of those coordinates. For example, the standard deviation of the given response = log(charge) variable is s y = q P (y i ¡ y) 2 =(n ¡ 1)
. The canonical form for variables is thus equivalent to "z-scores" of the form z i = (y i ¡ y) =s y . It follows that the sample sum-of-squares for each canonical-form variate is always z 0 z = (n ¡ 1) .
The equation for expected values in (1) can now be rewritten as
where i is the index for observations (1 · i · n), j is the index for predictor variables
(1 · j · P ), x 0 i = (x i1 ; :::; x iP ) is the i-th row of the original predictors X matrix, and s j denotes the original standard deviation in values in the j-th column of this X matrix.
The ordinary least squares estimate of¯is of the form 
, where ¤ is the diagonal matrix of principal axis
is the familiar R-squared statistic.
Shrinkage Regression Equations
Shrinkage/ridge estimates of¯are of the form b = b ¤ = G¢c, where ¢ = diag(± 1 ; :::; ± P ) is a diagonal matrix of principal axis "shrinkage factors," each on the range 0 · ± i · 1.
, which tends to be somewhat larger than the classical dispersion whenever the ± i are strictly less than 1 (and thus
There is insu¢cient space here to give full details about how normal-distribution-7 theory methods are used to estimate ¢ so as to maximize the likelihood that the resulting shrinkage/ridge estimator, b ¤ , exploits potential variance-bias tradeo¤s and achieves minimum mean-squared-error risk. Shrinkage/ridge methods were …rst introduced by Kennard(1970a,1970b) ; details of my maximum likelihood approach are given in Obenchain(1975 Obenchain( ,1995 . This methodology selects both the "shape" of the shrinkage path, Goldstein and Smith(1974) , and the "extent" of shrinkage along that path. The methodology has the potential to work very well in actual practice, as demonstrated by the simulation results of Gibbons(1981) . To form con…dence regions centered at shrunken estimates, the Bayesian highest posterior density methodology outlined by Lindley and Smith(1972) is used. A variety of free software implementations of my maximum likelihood shrinkage/ridge regression algorithms can be downloaded from the internet, Obenchain(1998a).
Di¤erences in Coe¢cient Estimates Between Datasets
Again, the regression models considered in Croghan et al.(1998) 
TRACE Displays, Etc., Etc.
The appendix to this paper contains graphical displays that show how the relative magnitudes and numerical signs of …tted coe¢cients change upon shrinkage as well as tables of the resulting elasticities (and 95% con…dence intervals for them.) Results are tabulated no only for log(charges) but also for "smeared" exp(predictions), as explained next.
Skewness in the Distribution of Charges
Health care charges cannot be negative. And, while the vast majority of patients may well incur relatively low charges, a few patients may incur very high charges.
As a result, typical charge distributions are highly (positively) skewed in the sense that, instead of having any point of symmetry, they tend to have a very long, heavy, right-hand "tail." In other words, the mean charge (arithmetic average) incurred is typically much, much higher than the median charge (50% point) or mode charge (most frequently observed value.) For example, the distribution of charges speci…cally for hospitalization may have median = mode = $0 because fewer than half of the patients under study have a hospitalization in any given year.
Monotonic, nonlinear transformations of charges are commonly applied in order to produce a statistical distribution that is much more nearly symmetric; i.e. one in which the mean, median and mode are all nearly equal. The transformed distribu-tion can then be much more realistically approximated by a "normal" (bell-shaped) distribution. A square-root transformation is sometimes used for this, but all transformed values then remain strictly non-negative (i.e. bounded from below rather than unbounded.) Natural logarithms (base e = 2.71828...) can be applied as long as all observed charges are strictly positive; log transformations map the value 0 to minus in…nity, ¡1: Furthermore, a log transformation applied to strictly positive charges yields an unbounded variable; one that can assume all values strictly between ¡1
and +1, like a true normal distribution.
While statistical models for log(charges) can be more "realistic" than models of charges, the …nal step in the analysis is usually to re-express results back in terms of the original charge units. The main problem that then arises is that statistics of the form predicted charge = exp[predicted log(charge)] typically tend to be severely biased downward. For example, suppose that the true distribution of y = log(charges) actually was normal with speci…ed mean ¹ and variance ¾
2
. The mean value of exp (y) is then
In other words, the mean of the charge = exp(y) distribution then depends upon the variance as well as upon the mean of the distribution of y = log(charge).
Duan(1983) describes this phenomenon as "unbiased and consistent quantities on the transformed (y) scale usually do not retransform into unbiased or consistent quantities on the untransformed (charges) scale." To adjust for this downward bias, the nonparametric "smearing estimate" of Duan(1983) is of the form
In other words, the smeared prediction is obtained by simply multiplying exp(predicted y at x o ) by a factor that does not depend upon x o . This factor is the average value of exp(residual) over all n observations in the regression, where residuals are de…ned as usual by b ² i = observed y i minus the predicted y at x = x i (rather than predictions at the "target" regressor combination, x = x o .) Now, note that the average value of b ² i is 0, where exp(0) = 1. Thus negative residuals contribute exp(b ² i )
terms that fall somewhere in the range from 0 to 1, while positive residuals contribute exp(b ² i ) terms in the unbounded range from 1 to +1. Thus the Duan(1983) smearing factor is typically greater than one.
The table below lists numerical values for this smearing factor in the multiple regression models discussed both in the original manuscript (1996) (1997) and in the revised/published version of Croghan et al.(1998) .
Original 1990-92 Sample Number of Patients 
Equations for Predictions and Forecasts
The dispersion information from equation (1) can be combined with equation (2) by writing
where the error terms, » 1 , ..., » n , are interchangeable random variables with mean zero and variance ¾ 2 ¢(n ¡ 1) =n . (The » i variates cannot be statistically independent because they always sum to exactly zero.)
Equation ( For this purpose, we multiply both sides of (5) by s y and move the y term to the right hand side of the equation to get...
where the b » term will always be zero when making point predictions of averages and forecasts for individual patients.
On the other hand, the variability in b y needs to be accounted for when forming con…dence limits. Thus, when forming 100(1 ¡ ®)% upper or lower con…dence limits on log(charge) forecast for an individual patient (outside the current sample of n), the contribution from the s y ¢ b » term will be § tscore ¢ s y ¢ b ¾, where tscore is the upper 100(1 ¡ ®=2)% point of the student's t distribution with (n ¡ P ¡ 1)
degrees-of-freedom.
The uncertainty in the linear combination of b estimates de…ned by the predictor variable z-score vector z
,...,
] is estimated using the quadratic
and the uncertainty in y is given by the familiar formula V ar(y) = s 2 y =n: In particular, note that for predictions at the X variable centroid (x = x), that z x = 0, the predicted log(charge) is y, and that d V ar(z x ) = 0.
In summary, we have
Furthermore, the upper and lower 100(1 ¡ ®)% con…dence limits on b y(x o ) as a prediction of average log(charges) are of the form
where tscore is again the upper 100(1 ¡ ®=2)% point of the student's t distribution with (n ¡ P ¡ 1) degrees-of-freedom.
The upper and lower 100(1 ¡ ®)% con…dence limits on b y(x o ) as a forecast for an individual patient can be much wider
Finally, remember that these estimates and limits are to be retransformed back to the charges scale and smeared as in equation (4) to yield
Incremental E¤ects for Mutually Exclusive Classes
To identify di¤erences in treatment and/or covariate characteristics between patients, multiple regression models commonly employ so-called "dummy" or "indicator" X variables. For each individual patient, these variables assume one of only two possible numerical values. Speci…cally, zero => absence while one => presence of a characteristic or treatment. Thus, if the …rst column of X, namely x 1 , is an indicator variable of this form, then x 1 is the fraction of patients for which the corresponding treatment or characteristic is present. Furthermore, the sample standard deviation of an indicator variable is of the special form
In other words, the z-scores associated with x 1 = 0, x 1 = x 1 , and x 1 = 1 are
respectively. Predictions and forecasts for speci…ed values of indicator variables are thus easily made using equations (8) through (11).
Special considerations may have to be applied, however, when a multiple linear regression model contains several indicator variables that, together, de…ne mutually exclusive and collectively exhaustive classes of patients.
First of all, if there are a total of K such classes, then regression models that contain an overall intercept term will usually contain only (K-1) such indicator variables.
This convention allows¯to be "estimable" by ordinary-least-squares. (Speci…cally, if all K indicator variables were included, then the sum of those K columns in the X matrix would be a column of ones, the Z 0 Z matrix would be singular, and (Z 0 Z)
¡1
would not exist!)
When K=2, it is clear that only one indicator variable is needed because the second indicator would always equal (1 minus the …rst indicator.) In other words, there would always be a "perfect" correlation of ¡1 between these two indicator variables. And the prediction or forecast at x 2 = x o is always the same as the prediction or forecast
However, when K¸3 mutually exclusive and collectively exhaustive classes are to be included, things get more complicated. Suppose that the indicator variables for the …rst (K-1) out of K classes are the ones included in the multiple regression model.
In this case, it is clear how to make the prediction or forecast when any one x k = 1 within 1 · k < K. After all, x k = 1 means that all other x j = 0 for j 6 = k. Similarly, it is clear how to made the prediction or forecast for x 1 = x 2 = ::: = x K¡1 = 0; this is the prediction or forecast for a patient diagnosed into the …nal category, the one with no indicator variable included in the multiple regression model.
The problem is... "What is the prediction or forecast most appropriate when all we know is that x k = 0 for the k-th class?" In other words, the only information we are given is that one, single diagnosis does NOT apply to that patient.
The solution stems from realizing that, if x k = 0, then exactly one x j = 1 for j 6 = k, while all other such x j = 0. Since we don't know which x j is one, we form a weighted average of predictions, where the weights are the estimated conditional
probabilities that x j = 1 given that x k = 0 for all j 6 = k :
where
The overall "incremental e¤ect" of a single class, k, within K¸3 mutually exclusive and exhaustive classes is then...
where f j = exp( b j =s j ) for 1 · j < K and f K´1 .
Summary
The calculations described here tend to be somewhat complicated, but they are actually quite easy to implement in a spreadsheet program such as Microsoft Excel 
